Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 24, 2010

View Archived Issues

Bromotetrandrine well tolerated and slowly cleared in healthy volunteers

Genetic association between GCH1 variants and a delay in the onset of cancer pain identified

Anacor discloses new PDE4 inhibitor with anti-inflammatory potential

ROCK-2 inhibitors identified by sanofi-aventis

New drug delivery agents described by University of Missouri-Kansas City

Roche presents full-year results of 2009

Bayer Schering discloses novel mineralocorticoid receptor antagonists

EnVivo claims novel phosphodiesterase 10 inhibitors

Korean researchers discover novel antimitotic agents

Antibody-conjugated magnetic-vortex microdiscs induce cancer cell death in vitro

Candidate plasma protein biomarkers for depression and schizophrenia identified

Roche reports on global phase III Avastin trial in stomach cancer

Extending preventive tuberculosis treatment may reduce illness in patients with HIV

Galapagos completes phase I trial of GLPG-0259 for RA

Catalyst and NIDA to initiate phase IIb trial of CPP-109 for cocaine addiction

FDA does not approve Forest Laboratories' sNDA for Bystolic

Merrimack begins phase I/II trial of MM-121/Tarceva in NSCLC

EMA recommends orphan drug status for Aprea's APR-246 for AML

MEND receives Bill and Melinda Gates Foundation grant to further develop malaria vaccine

Aradigm begins dosing in phase IIb trial of ARD-3100 in BE

Galapagos identifies third candidate drug in arthritis alliance with GSK

Transcept presents update on FDA approval of Intermezzo for insomnia

Catalyst presents update on development plans for CPP-115

European CHMP issues two positive opinions for GSK's Tyverb and Votrient in cancer

Cephalon to acquire Ception following results from phase II Cinquil trial in asthma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...